BMJ11d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ13d
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to ...
BMJ8d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
7 CIRI/Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University, Frankfurt, ...
BMJ2d
AB1149 SEX DISTRIBUTION IN PSORIATIC ARTHRITIS: SYSTEMATIC LITERATURE REVIEW
Background The prevalence of psoriatic arthritis (PsA) is considered equal in male and female patients but recent studies in cohorts of PsA it has been observed that women are more dominant in sex ...
BMJ13d
L-arginine metabolism inhibits arthritis and inflammatory bone loss
Objectives To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss. Methods L-arginine was applied to three arthritis models (collagen-induced arthritis ...
BMJ9d
Rituximab for IgG4-related disease: a prospective, open-label trial
Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in an open-label pilot trial. Methods We treated 30 IgG4-RD patients with two doses of RTX (1000 mg each). The ...
BMJ12d
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis
Objectives Myositis is a heterogeneous family of diseases that includes dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotising myopathy (IMNM), inclusion body myositis (IBM), ...
BMJ8d
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus
Correspondence to Dr Keishi Fujio, Department of Allergy and Rheumatology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; fujiok-int{at}h.u-tokyo.ac.jp; Dr Yukiko Iwasaki, Department of Palliative ...
BMJ4d
Baseline predictors of different types of treatment success in rheumatoid arthritis
Objective To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures. Methods We used data from three rheumatoid arthritis (RA) ...
BMJ5mon
Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis
Objectives Rheumatoid arthritis (RA) is an autoimmune disease characterised by aggressive fibroblast-like synoviocytes (FLSs). Very few RA patients-derived FLSs (RA-FLSs)-specific surface signatures ...
BMJ3d
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and ...
BMJ11d
Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
Objectives Haematopoietic stem and progenitor cells (HSPCs) are multipotent cells giving rise to both myeloid and lymphoid cell lineages. We reasoned that the aberrancies of immune cells in systemic ...